Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart patch could replace heart scans

NCT ID NCT07158450

Knowledge-focused Sponsor: Skribe Medical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a wearable sensor can accurately estimate the heart's pumping ability (LVEF) compared to standard ultrasound. Researchers will enroll 500 adults already scheduled for an echocardiogram. The goal is to develop a simpler, more accessible way to monitor heart function in conditions like heart failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults (≥18 years) recruited from participating cardiology clinics. Participants are assigned to one of three cohorts by transthoracic echocardiography (TTE): Healthy (no known structural heart disease; LVEF ≥ 55%), Borderline/Possibly reduced LVEF (LVEF 40-54% or clinical concern for decline), and Reduced LVEF (LVEF \< 40%). The population is intended to span the full spectrum of systolic function for model training and evaluation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Undergoing an echocardiogram irrespective of participation in this study * Willing and able to provide informed consent prior to any study-related activity Exclusion Criteria: * Have a documented allergy to potential tissue contacting system materials * Have any condition that would cause inaccurate TTE measurements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiotoxicity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cardiotoxicity heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiotoxicity Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cardiology Consultants of Philadelphia

    Yardley, Pennsylvania, 19067, United States

  • Cardiovascular Institute of the South

    Houma, Louisiana, 70360, United States

  • Clearwater Cardiovascular Consultants

    Clearwater, Florida, 33756, United States

  • Colorado Heart and Vascular

    Golden, Colorado, 80401, United States

  • Midwest Cardiovascular Institute

    Naperville, Illinois, 60540, United States

  • Stern Cardiovascular Center

    Germantown, Tennessee, 38138, United States

  • Strong Memorial Hospital

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.